These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11678206)

  • 1. Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow.
    Dührsen U; Martinez T; Vohwinkel G; Ergün S; Sun L; McMahon G; Dürig J; Hossfeld DK; Fiedler W
    Growth Factors; 2001; 19(1):1-17. PubMed ID: 11678206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
    Spiekermann K; Faber F; Voswinckel R; Hiddemann W
    Exp Hematol; 2002 Jul; 30(7):767-73. PubMed ID: 12135675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S; Laird D; Cherrington JM; Knox SJ
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
    Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
    Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human uterine myometrial smooth muscle cell proliferation and vascular endothelial growth-factor production in response to platelet-derived growth factor.
    Taniguchi Y; Morita I; Kubota T; Murota S; Aso T
    J Endocrinol; 2001 Apr; 169(1):79-86. PubMed ID: 11250649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
    Sun L; Tran N; Liang C; Tang F; Rice A; Schreck R; Waltz K; Shawver LK; McMahon G; Tang C
    J Med Chem; 1999 Dec; 42(25):5120-30. PubMed ID: 10602697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF is major stimulator in model of choroidal neovascularization.
    Kwak N; Okamoto N; Wood JM; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3158-64. PubMed ID: 10967078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.
    Gerber HP; Malik AK; Solar GP; Sherman D; Liang XH; Meng G; Hong K; Marsters JC; Ferrara N
    Nature; 2002 Jun; 417(6892):954-8. PubMed ID: 12087404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1.
    Moore MA; Hattori K; Heissig B; Shieh JH; Dias S; Crystal RG; Rafii S
    Ann N Y Acad Sci; 2001 Jun; 938():36-45; discussion 45-7. PubMed ID: 11458524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth.
    Ratajczak MZ; Ratajczak J; Machalinski B; Majka M; Marlicz W; Carter A; Pietrzkowski Z; Gewirtz AM
    Br J Haematol; 1998 Dec; 103(4):969-79. PubMed ID: 9886308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
    Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
    J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
    Heryanto B; Lipson KE; Rogers PA
    Reproduction; 2003 Mar; 125(3):337-46. PubMed ID: 12611597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment.
    Bautz F; Rafii S; Kanz L; Möhle R
    Exp Hematol; 2000 Jun; 28(6):700-6. PubMed ID: 10880756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
    Arbiser JL; Larsson H; Claesson-Welsh L; Bai X; LaMontagne K; Weiss SW; Soker S; Flynn E; Brown LF
    Am J Pathol; 2000 Apr; 156(4):1469-76. PubMed ID: 10751370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
    Angelov L; Salhia B; Roncari L; McMahon G; Guha A
    Cancer Res; 1999 Nov; 59(21):5536-41. PubMed ID: 10554031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.